DongKook Pharmaceutical Co. Ltd
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durak… Read more
DongKook Pharmaceutical Co. Ltd (086450) - Net Assets
Latest net assets as of September 2025: ₩743.40 Billion KRW
Based on the latest financial reports, DongKook Pharmaceutical Co. Ltd (086450) has net assets worth ₩743.40 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.04 Trillion) and total liabilities (₩293.92 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩743.40 Billion |
| % of Total Assets | 71.67% |
| Annual Growth Rate | 13.9% |
| 5-Year Change | 65.05% |
| 10-Year Change | 240.14% |
| Growth Volatility | 3.37 |
DongKook Pharmaceutical Co. Ltd - Net Assets Trend (2013–2024)
This chart illustrates how DongKook Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DongKook Pharmaceutical Co. Ltd (2013–2024)
The table below shows the annual net assets of DongKook Pharmaceutical Co. Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩678.98 Billion | +17.84% |
| 2023-12-31 | ₩576.17 Billion | +14.79% |
| 2022-12-31 | ₩501.94 Billion | +10.42% |
| 2021-12-31 | ₩454.57 Billion | +10.50% |
| 2020-12-31 | ₩411.37 Billion | +13.36% |
| 2019-12-31 | ₩362.87 Billion | +15.93% |
| 2018-12-31 | ₩313.02 Billion | +18.60% |
| 2017-12-31 | ₩263.94 Billion | +11.22% |
| 2016-12-31 | ₩237.32 Billion | +18.89% |
| 2015-12-31 | ₩199.62 Billion | +13.06% |
| 2014-12-31 | ₩176.57 Billion | +8.83% |
| 2013-12-31 | ₩162.24 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to DongKook Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 55820829984000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩558.21 Billion | 92.50% |
| Common Stock | ₩22.23 Billion | 3.68% |
| Other Components | ₩23.04 Billion | 3.82% |
| Total Equity | ₩603.48 Billion | 100.00% |
DongKook Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of DongKook Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Telecom Argentina S.A
PINK:TCMFF
|
$295.01 Million |
|
Xinlei Compressor Co. Ltd. A
SHE:301317
|
$295.02 Million |
|
AGARWALEYE
NSE:AGARWALEYE
|
$295.11 Million |
|
ENDUR ASA NK 050
F:4ZT0
|
$295.15 Million |
|
Inst Diagnosti
SN:INDISA
|
$294.91 Million |
|
Jiangsu Jiuwu Hi-Tech Co Ltd
SHE:300631
|
$294.88 Million |
|
Qingdao Daneng Environmental Protection Equipment Co Ltd
SHG:688501
|
$294.74 Million |
|
BOE Varitronix Limited
PINK:VARXF
|
$294.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DongKook Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 544,694,047,110 to 603,477,008,790, a change of 58,782,961,680 (10.8%).
- Net income of 61,218,952,620 contributed positively to equity growth.
- Dividend payments of 8,313,065,580 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩61.22 Billion | +10.14% |
| Dividends Paid | ₩8.31 Billion | -1.38% |
| Other Changes | ₩5.88 Billion | +0.97% |
| Total Change | ₩- | 10.79% |
Book Value vs Market Value Analysis
This analysis compares DongKook Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.32x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.36x to 1.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩5399.87 | ₩18140.00 | x |
| 2017-12-31 | ₩6005.66 | ₩18140.00 | x |
| 2018-12-31 | ₩7122.52 | ₩18140.00 | x |
| 2019-12-31 | ₩8256.85 | ₩18140.00 | x |
| 2020-12-31 | ₩9360.27 | ₩18140.00 | x |
| 2021-12-31 | ₩10343.19 | ₩18140.00 | x |
| 2022-12-31 | ₩11419.31 | ₩18140.00 | x |
| 2023-12-31 | ₩12390.02 | ₩18140.00 | x |
| 2024-12-31 | ₩13725.27 | ₩18140.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DongKook Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.14%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.54%
- • Asset Turnover: 0.85x
- • Equity Multiplier: 1.58x
- Recent ROE (10.14%) is below the historical average (12.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 10.36% | 7.87% | 0.98x | 1.35x | ₩575.42 Million |
| 2014 | 11.97% | 9.33% | 0.93x | 1.38x | ₩3.47 Billion |
| 2015 | 13.74% | 10.55% | 0.95x | 1.38x | ₩7.46 Billion |
| 2016 | 17.13% | 13.13% | 0.95x | 1.37x | ₩16.93 Billion |
| 2017 | 15.00% | 11.16% | 0.95x | 1.41x | ₩13.21 Billion |
| 2018 | 15.00% | 11.71% | 0.83x | 1.53x | ₩15.65 Billion |
| 2019 | 15.52% | 11.68% | 0.89x | 1.50x | ₩20.02 Billion |
| 2020 | 13.59% | 10.00% | 0.84x | 1.61x | ₩14.79 Billion |
| 2021 | 11.08% | 8.47% | 0.79x | 1.65x | ₩4.89 Billion |
| 2022 | 10.54% | 7.99% | 0.86x | 1.53x | ₩2.70 Billion |
| 2023 | 8.66% | 6.45% | 0.87x | 1.54x | ₩-7.29 Billion |
| 2024 | 10.14% | 7.54% | 0.85x | 1.58x | ₩871.25 Million |
Industry Comparison
This section compares DongKook Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $96,196,506,488
- Average return on equity (ROE) among peers: -9.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DongKook Pharmaceutical Co. Ltd (086450) | ₩743.40 Billion | 10.36% | 0.40x | $294.94 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |